Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Clinical trials sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., explained in plain language.
A pharmaceutical R&D subsidiary of Sino Biopharmaceutical, focusing on drug development.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot could tame seasonal sniffles for good? Results expected Nov 2026 (estimated)
- New antibody injection aims to tame COPD Flare-Ups Results expected Dec 2026 (estimated)
- New antibody injection could shrink nasal polyps and ease breathing Results expected Mar 2027 (estimated)
- Can a smart drug deliver a toxic payload directly to cancer cells? Results expected Aug 2027 (estimated)
-
Can a Muscle-Blocking antibody help fight obesity? a new trial seeks answers
Disease control Not yet recruitingThis phase 1 trial tests an experimental drug called TQF6422 in healthy adults who are overweight or obese. The drug is an antibody that blocks certain proteins in the body, which may affect how the body regulates muscle and fat. Researchers give single and multiple doses to see …
Phase 1 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New antibody injection takes aim at Hard-to-Treat head and neck cancer
Disease control Not yet recruitingThis study tests a new drug called TQB2922, given as a shot under the skin, for people with head and neck cancer that has come back or spread. The drug is a special antibody that targets two proteins (EGFR and c-Met) involved in cancer growth. The trial has two parts: first, find…
Phase 1/2 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug aims to outsmart recurrent lymphoma
Disease control Not yet recruitingThis Phase 3 trial tests a new drug called TQB2825, a bispecific antibody that targets both CD3 and CD20 proteins, against standard immunotherapy for people with follicular lymphoma that has returned or not responded to treatment. About 228 participants will be randomly assigned …
Phase 3 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC